Use your antibodies-online credentials, if available.
抗Mouse (Murine) Phospholipase C gamma 2 抗体:
抗Rat (Rattus) Phospholipase C gamma 2 抗体:
抗Human Phospholipase C gamma 2 抗体:
Human Polyclonal Phospholipase C gamma 2 Primary Antibody for IHC - ABIN966863
Kim, Sekiya, Poulin, Bae, Rhee: Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. in Molecular and cellular biology 2004
Show all 2 Pubmed References
Human Monoclonal Phospholipase C gamma 2 Primary Antibody for ICS - ABIN1177150
Holodick, Tumang, Rothstein: Continual signaling is responsible for constitutive ERK phosphorylation in B-1a cells. in Molecular immunology 2009
Human Polyclonal Phospholipase C gamma 2 Primary Antibody for IF (p), IHC (p) - ABIN700375
Diaz-Flores, Goldschmidt, Depeille, Ng, Akutagawa, Krisman, Crone, Burgess, Williams, Houseman, Shokat, Sampath, Bollag, Roose, Braun, Shannon: PLC-? and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. in Science signaling 2013
Syk (显示 SYK 抗体)-induced signals in bone marrow stromal cell lines are mediated by phospholipase C (显示 PLC 抗体) gamma1 (PLCgamma1 (显示 PLCG1 抗体)) in osteogenesis and PLCgamma2 in adipogenesis.
Results show that mice with the mutated Plcg2 gene were less prone to transformation into MALT lymphomas as a result of elevated Treg numbers, and decrease of pro-inflammatory cytokines.
PLCgamma2 in clear cells plays an essential role in luminal expansion of the epididymis during the prepubertal period in mice
platelet activation through GPVI (显示 GP6 抗体) and alphaIIbbeta3 utilizes PLCgamma2 because PLCgamma1 (显示 PLCG1 抗体) levels are insufficient to support responsiveness, but that PLCgamma1 (显示 PLCG1 抗体) can restore responsiveness if expressed at levels normally achieved by PLCgamma2.
amarogentin prevents platelet activation through the inhibition of PLC (显示 HSPG2 抗体) gamma2-PKC (显示 PKC 抗体) cascade and MAPK (显示 MAPK1 抗体) pathway
PLCgamma2 and protein kinase C (显示 PKC 抗体) are important upstream signals that regulate myelopoiesis through cytokines.
inflammatory osteolysis can be abrogated by treatment with a molecule composed of the tandem SH2 (显示 MYO15 抗体) domains of PLCgamma2.
down-regulation of PLCgamma2-beta-catenin (显示 CTNNB1 抗体) pathway occurs in mice and humans and leads to myeloid-derived suppressor cells-mediated tumor expansion.
a novel role of the PLCgamma2-IP(3)-Ca(2 (显示 CA2 抗体)+) cascade in the LPS (显示 TLR4 抗体)-induced innate immune response pathway where release of intracellular Ca(2 (显示 CA2 抗体)+) mediates TLR4 (显示 TLR4 抗体) trafficking and subsequent activation of IRF3 (显示 IRF3 抗体).
VapB (显示 VAPB 抗体) positively regulates RANKL (显示 TNFSF11 抗体)-mediated osteoclastogenesis via PLCgamma2-Ca(2 (显示 CA2 抗体)+)-NFAT (显示 NFATC1 抗体) signaling
Data show that protein-altering changes are in PLCG2, ABI3 (显示 ABI3 抗体), and TREM2 (显示 TREM2 抗体) genes highly expressed in microglia and highlight an immune-related protein-protein interaction network in Alzheimer's disease.
Ocular manifestations of phospholipase-Cgamma2-associated antibody deficiency and immune dysregulation show mutations in the PLC (显示 HSPG2 抗体)[gamma]2 gene leading to aberrant function of immune cells and overproduction of interleukin-1 [beta] (IL-1 (显示 IL1A 抗体)[beta]).
R665W and L845F be referred to as allomorphic rather than hypermorphic mutations of PLCG2 Rerouting of the transmembrane signals emanating from BCR (显示 BCR 抗体) and converging on PLCgamma2 through Rac (显示 AKT1 抗体) in ibrutinib-resistant CLL cells may provide novel drug treatment strategies to overcome ibrutinib resistance mediated by PLCG2 mutations or to prevent its development in ibrutinib-treated CLL patients.
Data show that phospholipase Cgamma2 (PLCgamma2) is strongly expressed in B cell non-Hodgkin lymphoma and especially in a large subset of Diffuse large B-cell lymphoma (DLBCL).
Characterization of the effect of missense point-mutation at R665W in PLCG2 on signaling mechanisms of ibrutinib resistance in chronic lymphocytic leukemia cells.
amarogentin prevents platelet activation through the inhibition of PLC (显示 HSPG2 抗体) gamma2-PKC (显示 PRRT2 抗体) cascade and MAPK (显示 MAPK1 抗体) pathway
PLCG2 missense mutation is a risk factor in the development of steroid sensitive nephrotic syndrome in childhood.
The autoinhibitory C-terminal SH2 domain of phospholipase C (显示 PLC 抗体)-gamma2 stabilizes B cell receptor signalosome assembly.
The relationship between upstream tyrosine kinase (显示 TXK 抗体) SYK (显示 SYK 抗体) and its target, PLCgamma2, is maximally predictive and sufficient to distinguish chronic lymphocytic leukemia from healthy controls.
The protein encoded by this gene is a transmembrane signaling enzyme that catalyzes the conversion of 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate to 1D-myo-inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), using calcium as a cofactor. IP3 and DAG are second messenger molecules important for transmitting signals from growth factor receptors and immune system receptors across the cell membrane.
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-2
, 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2
, phosphoinositide phospholipase C-gamma-2
, phospholipase C-gamma-2
, phosphoinositide phospholipase C
, phospholipase C-IV
, phosphatidylinositol-specific phospholipase C